Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulmonary surfactant combined with budesonide for prevention and treatment of bronchopulmonary dysplasia in very preterm infants
ChiCTR2100048967Phase 4Recruiting
- Sponsor
- Maternal and Child Health Hospital of Hubei Province
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of budesonide and calf pulmonary surfactant in bronchopulmonary dysplasia (BPD) (4 arms), sponsored by Maternal and Child Health Hospital of Hubei Province. Primary endpoints: Incidence and severity of bronchopulmonary dysplasia, Physical development index and intellectual development index and 1 more. Started Jul 2021; status: recruiting.
02
Drugs
budesonidecalf pulmonary surfactant
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on ChiCTR2100048967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048967.